Free Newsletter

FEATURES >> 15 Top Blockbuster Contenders | 10 Promising Therapeutic Vaccines

Related Topics >> Gilead Sciences | Parion Sciences | GS9411

Parion gets $5M milestone from Gilead

December 4, 2008 — 2:31pm ET | By Maureen Martino

Idenix gets good news on hep C trial, but can't compete with Gilead
Gilead shares surge as hep C drug scores a cure for big patient population
Bristol bags hot hep C drug developer Inhibitex for $2.5B
Pharmasset drops testing of Hep C drug, peers suffer on Wall Street
Report: How savvy Pharmasset persuaded Gilead to boost its offer by 37%

Tools

Subscribe
Email
Print
Contact Author
Reprint

North Carolina' s Parion Sciences and Gilead have initiated a Phase I clinical trial of GS9411, and experimental therapy designed to increase airway hydration for the treatment of pulmonary disease. Parion will get a $5 million milestone payment from Gilead. Release

SHARE
WITH: